1-20 of 50
Gabriel N. Hortobagyi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research

Fabio Conforti, Laura Pala, Tommaso De Pas, Emma Zattarin, Chiara Catania, Emilia Cocorocchio, Giovanna Rossi, Daniele Laszlo, Marco Colleoni, Alberto Zambelli, Gabriel N. Hortobagyi, Javier Cortes, Martine J. Piccart, Mitch Dowsett, Richard D. Gelber, Giuseppe Viale
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1093–1103.
https://doi.org/10.1158/1078-0432.CCR-23-1836
Published: 15 March 2024
View article titled, Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
Open the PDF for Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research in another window
Journal Articles

Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer

Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E. Adrada, Qing-Qing Ding, Jason B. White, Elizabeth E. Ravenberg, Alyson R. Clayborn, Vicente Valero, Debu Tripathy, Senthilkumar Damodaran, Banu K. Arun, Jennifer K. Litton, Naoto T. Ueno, Rashmi K. Murthy, Bora Lim, Luis Baez, Xiaoxian Li, Aman U. Buzdar, Gabriel N. Hortobagyi, Alistair M. Thompson, Elizabeth A. Mittendorf, Gaiane M. Rauch, Rosalind P. Candelaria, Lei Huo, Stacy L. Moulder, Jeffrey T. Chang
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2878–2889.
https://doi.org/10.1158/1078-0432.CCR-21-3100
Published: 01 July 2022
View article titled, Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
Open the PDF for Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222

Halle C.F. Moore, William E. Barlow, George Somlo, Julie R. Gralow, Anne F. Schott, Daniel F. Hayes, Peter Kuhn, James B. Hicks, Lisa Welter, Philip A. Dy, Christina H. Yeon, Alison K. Conlin, Ernie Balcueva, Danika L. Lew, Debasish Tripathy, Lajos Pusztai, Gabriel N. Hortobagyi
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 611–617.
https://doi.org/10.1158/1078-0432.CCR-21-3131
Published: 15 February 2022
View article titled, A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
Open the PDF for A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222 in another window
Includes: Supplementary data
Journal Articles

Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial

Costanza Paoletti, William E. Barlow, Erin F. Cobain, Mattias Bergqvist, Rita S. Mehta, Julie R. Gralow, Gabriel N. Hortobagyi, Kathy S. Albain, Lajos Pusztai, Priyanka Sharma, Andrew K. Godwin, Alastair M. Thompson, Daniel F. Hayes, James M. Rae
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6115–6123.
https://doi.org/10.1158/1078-0432.CCR-21-1562
Published: 15 November 2021
View article titled, Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial
Open the PDF for Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial in another window
Includes: Supplementary data
Journal Articles

Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors

Xuexin He, Jiali Ji, Xiaolan Dai, Aiham Z. Qdaisat, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching J. Yeung
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5343–5352.
https://doi.org/10.1158/1078-0432.CCR-20-4162
Published: 01 October 2021
View article titled, Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors
Open the PDF for Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors in another window
Includes: Supplementary data
Journal Articles

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer

Clinton Yam, Er-Yen Yen, Jeffrey T. Chang, Roland L. Bassett, Jr, Gheath Alatrash, Haven Garber, Lei Huo, Fei Yang, Anne V. Philips, Qing-Qing Ding, Bora Lim, Naoto T. Ueno, Kasthuri Kannan, Xiangjie Sun, Baohua Sun, Edwin Roger Parra Cuentas, William Fraser Symmans, Jason B. White, Elizabeth Ravenberg, Sahil Seth, Jennifer L. Guerriero, Gaiane M. Rauch, Senthil Damodaran, Jennifer K. Litton, Jennifer A. Wargo, Gabriel N. Hortobagyi, Andrew Futreal, Ignacio I. Wistuba, Ryan Sun, Stacy L. Moulder, Elizabeth A. Mittendorf
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5365–5375.
https://doi.org/10.1158/1078-0432.CCR-21-0144
Published: 01 October 2021
View article titled, Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
Open the PDF for Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer

Xuexin He, Jiali Ji, Mei Tian, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching Jim Yeung
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7388–7395.
https://doi.org/10.1158/1078-0432.CCR-19-0463
Published: 13 December 2019
View article titled, Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer
Open the PDF for Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study

Costanza Paoletti, Jieling Miao, Emily M. Dolce, Elizabeth P. Darga, Madeline I. Repollet, Gerald V. Doyle, Julie R. Gralow, Gabriel N. Hortobagyi, Jeffrey B. Smerage, William E. Barlow, Daniel F. Hayes
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6089–6097.
https://doi.org/10.1158/1078-0432.CCR-19-0208
Published: 15 October 2019
View article titled, Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study
Open the PDF for Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study in another window
Includes: Supplementary data
Journal Articles

PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression

Shiping Jiao, Weiya Xia, Hirohito Yamaguchi, Yongkun Wei, Mei-Kuang Chen, Jung-Mao Hsu, Jennifer L. Hsu, Wen-Hsuan Yu, Yi Du, Heng-Huan Lee, Chia-Wei Li, Chao-Kai Chou, Seung-Oe Lim, Shih-Shin Chang, Jennifer Litton, Banu Arun, Gabriel N. Hortobagyi, Mien-Chie Hung
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3711–3720.
https://doi.org/10.1158/1078-0432.CCR-16-3215
Published: 13 July 2017
View article titled, PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Open the PDF for PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression in another window
Includes: Multimedia, Supplementary data
Journal Articles

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

Kelly K. Hunt, Cansu Karakas, Min Jin Ha, Anna Biernacka, Min Yi, Aysegul A. Sahin, Opoku Adjapong, Gabriel N. Hortobagyi, Melissa L. Bondy, Patricia A. Thompson, Kwok Leung Cheung, Ian O. Ellis, Sarah Bacus, W. Fraser Symmans, Kim-Anh Do, Khandan Keyomarsi
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 2991–3002.
https://doi.org/10.1158/1078-0432.CCR-16-2217
Published: 14 June 2017
View article titled, Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Open the PDF for Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis

Zahi Mitri, Rita Nanda, Kimberly Blackwell, Colleen M. Costelloe, Ilona Hood, Caimiao Wei, Abenaa M. Brewster, Nuhad K. Ibrahim, Kimberly B. Koenig, Gabriel N. Hortobagyi, Catherine Van Poznak, Mothaffar F. Rimawi, Stacy Moulder-Thompson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (23): 5706–5712.
https://doi.org/10.1158/1078-0432.CCR-15-2845
Published: 30 November 2016
View article titled, TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Open the PDF for TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis in another window
Journal Articles

Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer

Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, W. Fraser Symmans
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (20): 5265–5271.
https://doi.org/10.1158/1078-0432.CCR-14-0800
Published: 14 October 2014
View article titled, Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Open the PDF for Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

Hiroko Masuda, Keith A. Baggerly, Ying Wang, Ya Zhang, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam, Vicente Valero, Brian D. Lehmann, Jennifer A. Pietenpol, Gabriel N. Hortobagyi, W. Fraser Symmans, Naoto T. Ueno
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (19): 5533–5540.
https://doi.org/10.1158/1078-0432.CCR-13-0799
Published: 01 October 2013
View article titled, Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes
Open the PDF for Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes in another window
Includes: Supplementary data
Journal Articles

Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients

Antonio Giordano, Brian L. Egleston, David Hajage, Joseph Bland, Gabriel N. Hortobagyi, James M. Reuben, Jean-Yves Pierga, Massimo Cristofanilli, Francois-Clement Bidard
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (6): 1596–1602.
https://doi.org/10.1158/1078-0432.CCR-12-3137
Published: 14 March 2013
View article titled, Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients
Open the PDF for Establishment and Validation of Circulating Tumor Cell–Based Prognostic Nomograms in First-Line Metastatic Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

Kanwal P. Raghav, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. Blumenschein, Jr, Ana M. Gonzalez-Angulo
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (8): 2269–2277.
https://doi.org/10.1158/1078-0432.CCR-11-2830
Published: 16 April 2012
View article titled, cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
Open the PDF for cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes in another window
Journal Articles

Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer

Ana M. Gonzalez-Angulo, Takayuki Iwamoto, Shuying Liu, Huiqin Chen, Kim-Anh Do, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, W. Fraser Symmans, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1109–1119.
https://doi.org/10.1158/1078-0432.CCR-11-2762
Published: 14 February 2012
View article titled, Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer
Open the PDF for Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

Charles Coutant, Roman Rouzier, Yuan Qi, Jacqueline Lehmann-Che, Giampaolo Bianchini, Takayuki Iwamoto, Gabriel N. Hortobagyi, W. Fraser Symmans, Serge Uzan, Fabrice Andre, Hugues de Thé, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2591–2601.
https://doi.org/10.1158/1078-0432.CCR-10-1045
Published: 14 April 2011
View article titled, Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Open the PDF for Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

Ana M. Gonzalez-Angulo, Kirsten M. Timms, Shuying Liu, Huiqin Chen, Jennifer K. Litton, Jennifer Potter, Jerry S. Lanchbury, Katherine Stemke-Hale, Bryan T. Hennessy, Banu K. Arun, Gabriel N. Hortobagyi, Kim-Anh Do, Gordon B. Mills, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (5): 1082–1089.
https://doi.org/10.1158/1078-0432.CCR-10-2560
Published: 01 March 2011
View article titled, Incidence and Outcome of <em>BRCA</em> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Open the PDF for Incidence and Outcome of <em>BRCA</em> Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer in another window
Journal Articles

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer

Song Yao, William E. Barlow, Kathy S. Albain, Ji-Yeob Choi, Hua Zhao, Robert B. Livingston, Warren Davis, James M. Rae, I-Tien Yeh, Laura F. Hutchins, Peter M. Ravdin, Silvana Martino, Alan P. Lyss, C. Kent Osborne, Martin Abeloff, Gabriel N. Hortobagyi, Daniel F. Hayes, Christine B. Ambrosone
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (24): 6169–6176.
https://doi.org/10.1158/1078-0432.CCR-10-0281
Published: 16 December 2010
View article titled, Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
Open the PDF for Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer in another window
Journal Articles

Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

Adel Tabchy, Vicente Valero, Tatiana Vidaurre, Ana Lluch, Henry Gomez, Miguel Martin, Yuan Qi, Luis Javier Barajas-Figueroa, Eduardo Souchon, Charles Coutant, Franco D. Doimi, Nuhad K. Ibrahim, Yun Gong, Gabriel N. Hortobagyi, Kenneth R. Hess, W. Fraser Symmans, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (21): 5351–5361.
https://doi.org/10.1158/1078-0432.CCR-10-1265
Published: 31 October 2010
View article titled, Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer
Open the PDF for Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer in another window
Includes: Supplementary data